Lombardi Raffaella, Rodriguez Gabriela, Chen Suet Nee, Ripplinger Crystal M, Li Wenwen, Chen Junjie, Willerson James T, Betocchi Sandro, Wickline Samuel A, Efimov Igor R, Marian Ali J
Center for Cardiovascular Genetics, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, and Texas Heart Institute, Houston, TX, USA.
Circulation. 2009 Mar 17;119(10):1398-407. doi: 10.1161/CIRCULATIONAHA.108.790501. Epub 2009 Mar 2.
Cardiac hypertrophy, the clinical hallmark of hypertrophic cardiomyopathy (HCM), is a major determinant of morbidity and mortality not only in HCM but also in a number of cardiovascular diseases. There is no effective therapy for HCM and generally for cardiac hypertrophy. Myocardial oxidative stress and thiol-sensitive signaling molecules are implicated in pathogenesis of hypertrophy and fibrosis. We posit that treatment with N-acetylcysteine, a precursor of glutathione, the largest intracellular thiol pool against oxidative stress, could reverse cardiac hypertrophy and fibrosis in HCM.
We treated 2-year-old beta-myosin heavy-chain Q403 transgenic rabbits with established cardiac hypertrophy and preserved systolic function with N-acetylcysteine or a placebo for 12 months (n=10 per group). Transgenic rabbits in the placebo group had cardiac hypertrophy, fibrosis, systolic dysfunction, increased oxidized to total glutathione ratio, higher levels of activated thiol-sensitive active protein kinase G, dephosphorylated nuclear factor of activated T cells (NFATc1) and phospho-p38, and reduced levels of glutathiolated cardiac alpha-actin. Treatment with N-acetylcysteine restored oxidized to total glutathione ratio, normalized levels of glutathiolated cardiac alpha-actin, reversed cardiac and myocyte hypertrophy and interstitial fibrosis, reduced the propensity for ventricular arrhythmias, prevented cardiac dysfunction, restored myocardial levels of active protein kinase G, and dephosphorylated NFATc1 and phospho-p38.
Treatment with N-acetylcysteine, a safe prodrug against oxidation, reversed established cardiac phenotype in a transgenic rabbit model of human HCM. Because there is no effective pharmacological therapy for HCM and given that hypertrophy, fibrosis, and cardiac dysfunction are common and major predictors of clinical outcomes, the findings could have implications in various cardiovascular disorders.
心肌肥厚是肥厚型心肌病(HCM)的临床特征,不仅是HCM发病和死亡的主要决定因素,也是许多心血管疾病的主要决定因素。目前尚无针对HCM以及一般心肌肥厚的有效治疗方法。心肌氧化应激和硫醇敏感信号分子与肥厚和纤维化的发病机制有关。我们推测,用N-乙酰半胱氨酸(谷胱甘肽的前体,细胞内最大的抗氧化硫醇池)治疗可逆转HCM中的心肌肥厚和纤维化。
我们用N-乙酰半胱氨酸或安慰剂治疗了2岁的β-肌球蛋白重链Q403转基因兔,这些兔已出现心肌肥厚且收缩功能保留,治疗时间为12个月(每组n = 10)。安慰剂组的转基因兔出现心肌肥厚、纤维化、收缩功能障碍、氧化型谷胱甘肽与总谷胱甘肽比值升高、硫醇敏感的活性蛋白激酶G活化水平升高、活化T细胞核因子(NFATc1)去磷酸化以及p38磷酸化水平升高,而谷胱甘肽化心肌α-肌动蛋白水平降低。用N-乙酰半胱氨酸治疗可恢复氧化型谷胱甘肽与总谷胱甘肽比值,使谷胱甘肽化心肌α-肌动蛋白水平正常化,逆转心肌和心肌细胞肥厚以及间质纤维化,降低室性心律失常的倾向,预防心脏功能障碍,恢复活性蛋白激酶G的心肌水平,并使NFATc1和p38去磷酸化。
用N-乙酰半胱氨酸(一种安全的抗氧化前体药物)治疗可逆转人HCM转基因兔模型中已有的心脏表型。由于目前尚无针对HCM的有效药物治疗方法,且肥厚、纤维化和心脏功能障碍是临床结局的常见且主要预测因素,因此这些发现可能对各种心血管疾病具有重要意义。